New dual-target drug may help overcome immunotherapy resistance in pancreatic cancer
Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%. There are only two treatment regimens available with limited efficacy. Pancreatic cancers do not respond to immunotherapy where the body's immune system attacks tumor cells.
ORIGINAL SOURCE →via Medical Xpress
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] Gaza-bound Global Sumud Flotilla approached by warships, activists claim
- [CONFLICT] Israeli study finds plants absorb nutrients from airborne dust, challenging root-only theory
- [CONFLICT] Israel just quadrupled its PR budget to $730M, experts claim it won’t work
- [CONFLICT] Yobe gov appoints acting SSG
- [CONFLICT] DRW chief slams 'ridiculous' OCC stablecoin rule